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Abstract
Bartter and Gitelman syndromes are rare inherited tubulopathies characterized by hypokalaemic, hypochloraemic metabolic
alkalosis. They are caused by mutations in at least 7 genes involved in the reabsorption of sodium in the thick ascending limb
(TAL) of the loop of Henle and/or the distal convoluted tubule (DCT). Different subtypes can be distinguished and various
classifications have been proposed based on clinical symptoms and/or the underlying genetic cause. Yet, the clinical phenotype
can show remarkable variability, leading to potential divergences between classifications. These problems mostly relate to
uncertainties over the role of the basolateral chloride exit channel CLCNKB, expressed in both TAL and DCT and to what
degree the closely related paralogue CLCNKA can compensate for the loss of CLCNKB function. Here, we review what is
known about the physiology of the transport proteins involved in these disorders. We also review the various proposed classi-
fications and explain why a gene-based classification constitutes a pragmatic solution.
Keywords Bartter syndrome . Gitelman syndrome . EASTsyndrome . Tubulopathy .Metabolic alkalosis . Hypokalaemia
Introduction
Physiology and pathophysiology
Small solutes like sodium and potassium are freely filtered by
the glomerulus and will subsequently be reabsorbed in differ-
ent parts of the nephron. Approximately 99% of the total
amount of filtered sodium will be reabsorbed: around 70–
80% in the proximal tubule (PT), 10–20% in the thick ascend-
ing limb of the loop of Henle (TAL), another 5–10% in the
distal convoluted tubule (DCT), and around 2–5% in the
collecting duct (CD). The percentages of potassium being
reabsorbed in the PT and TAL are more or less comparable
to those of sodium. However, in the more distal DCT and the
CD, also known as the aldosterone-sensitive part of the
nephron, potassium can be actively secreted. Inherited or ac-
quired factors (the latter including drugs) that disrupt the func-
tion of specific transporters in these nephron segments can
cause a range of symptoms, the most common being polyuria
and polydipsia, electrolyte abnormalities, and acid-base dis-
turbances [1–4].
Salt reabsorption in the TAL
In the TAL, sodium is reabsorbed from the tubular lumen
into the cell together with potassium and two chloride mol-
ecules by the luminal sodium-potassium-2 chloride
cotransporter (NKCC2), which can be blocked by loop di-
uretics (Fig. 1). Next, chloride leaves the cell via basolateral
chloride channels, mainly CLCNKB and, presumably to a
lesser degree, also through CLCNKA. The uncertainty about
the exact nature of the chloride exit pathway stems mainly
from the fact that these 2 chloride channels are highly ho-
mologous. They are encoded by 2 adjacent genes on chro-
mosome 1, the result of an ancient gene duplication [5].
Thus, antibodies that can distinguish between these channels
have not yet been identified, making exact localisation diffi-
cult. Using mostly a technique called in situ hybridization,
which assesses mRNA expression, some differences in lo-
calization have been reported, showing that CLCNKA (or its
orthologues in rodents) is mainly expressed in the loop of
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Henle, including the thin descending limb, whereas
CLCNKB is predominantly expressed in the thick ascending
limb, as well as the DCT, but also in the collecting duct [5].
Clues for the exact roles of these channels in man are mainly
inferred from clinical observations. Loss of function of
CLCNKB causes Bartter syndrome type 3 (BS3), which
clearly establishes CLCNKB as the key exit pathway for
chloride in the TAL. In contrast, isolated loss of function of
CLCNKA has not yet been associated with a clinical pheno-
type in man, despite actively looking for mutations in the
gene encoding this transporter in unexplained cases of
Bartter syndrome. If CLCNKA is knocked-out in mice, there
is impairment of urinary concentration, but no apparent salt
wasting [6]. Yet, the combined loss of function of both chan-
nels causes a more severe type of Bartter syndrome, so-
called Bartter syndrome type 4b (BS4b), suggesting that
CLCNKA does have a complementary role in mediating
chloride exit [7]. Both CLCNKA and CLCNKB channels
depend on the presence of a subunit called Barttin to enable
chloride transport. Loss of function of this subunit causes
Bartter syndrome type 4a (BS4a), which is clinically similar
to BS4b [8]. Sodium is then transported out of the cell by the
basolateral Na-K-ATPase. This transporter is present in the
cell membrane of virtually all cells in our body in order to
maintain the electrochemical gradients for sodium and po-
tassium crucial for cell function. It actively transports three
sodium molecules out and two potassium molecules into the
cell. Lastly, potassium recycles back into the tubular lumen
via the potassium channel KCNJ1 (also called ROMK). This
recycling establishes the lumen-positive transepithelial po-
tential that is needed for the paracellular uptake of cations,
including calcium and magnesium via claudins (Fig. 1)
[2–4]. It is important to note that the macula densa, the site
of tubuloglomerular feedback (TGF) is part of the TAL.
Thus, impaired salt reabsorption in TAL leads to a Bshort-
circuiting^ of TGF with increased renin production, which is
irrespective of volume status [9–11].
The clinical consequences of impaired TAL salt transport:
the Bloop^ phenotype
Impaired salt reabsorption in the TAL leads to specific clinical
consequences that can be explained by the underlying molec-
ular physiology: the loss of salt, as well as the Bshort-
circuited^ TGF lead to highly elevated renin and aldosterone
levels causing hypokalaemic, hypochloraemic metabolic
Fig. 1. Electrolyte transport in the TAL. The NKCC2 transporter imports
one sodium, one potassium, and two chloride ions from the lumen into the
cell. This transporter can be blocked by loop diuretics, inherited
dysfunction causes Bartter syndrome type 1. Mutations in the gene
encoding MAGE-D2 result in a transient decreased expression of
NKCC2, thus causing Bartter syndrome type 5. Chloride leaves the cell
via the basolateral chloride transporters CLCNKB and, presumably,
CLCNKA, both of which need the Barttin subunit in order to function.
Mutations in CLCNKB cause Bartter syndrome type 3 and in Barttin
cause Bartter syndrome type 4a; combined dysfunction of the
CLCNKA and CLCNKB channels causes Bartter syndrome type 4b.
Sodium leaves the cell via the basolateral Na-K-ATPase that actively
exports three sodium ions and imports two potassium ions. Potassium
subsequently leaves the cell via the luminal KCNJ1 channel, mutations
in which cause Bartter syndrome type 2. The luminal potassium concen-
tration is the main driving force for the paracellular uptake of calcium and
magnesium, which is facilitated by a lumen-positive transepithelial po-
tential. Therefore, hypercalciuria with nephrocalcinosis and
hypermagnesuria is typically seen in Bartter syndromes type 1
(NKCC2), type 2 (KCNJ1), and type 5 (MAGE-D2), while it can be
variable in Bartter syndromes type 3 (CLCNKB), type 4a (Barttin), and
type 4b (combined CLCNKA and CLCNKB)
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alkalosis. In addition, the loss of the lumen-positive
transepithelial voltage gradient leads to impaired paracellular
cation uptake, mostly manifesting as hypercalciuria. Lastly, as
the TAL is critical for urinary concentration by dilution of
tubular fluid and generation of the interstitial concentration
gradient, patients have a urinary concentrating defect, typical-
ly isosthenuria, although some have hyposthenuria [12]. The
pharmacologic equivalent to the Bloop^ phenotype are obvi-
ously loop diuretics, the use of which results in the same blood
and urine electrolyte abnormalities [13].
Salt transport in the DCT
In the DCT, sodium and chloride are transported into the cell
by the luminal sodium-chloride cotransporter (NCC), which
can be blocked by thiazide diuretics (Fig. 2). Chloride subse-
quently exits the cell by the basolateral CLCNKB with its
Barttin subunit. Again, sodium is exported and potassium is
imported by the basolateral Na-K-ATPase. The activity of this
transporter in the DCT depends on the activity of the
basolateral potassium channel KCNJ10 (also called Kir4.1),
which enables the recycling of potassium across the
basolateral membrane, thus ensuring a steady supply for the
Na-K-ATPase. The importance of this basolateral recycling is
highlighted by loss-of-function mutations in this gene leading
to EAST (also called SeSAME) syndrome, which includes a
Gitelman-like tubulopathy [14, 15]. In this part of the neph-
ron, calcium and magnesium are reabsorbed via the transcel-
lular route. Calcium enters the cell via the luminal transient
receptor potential cation channel subfamily V member 5
(TRPV5). It leaves the cell via the basolateral Na/Ca exchang-
er, which removes calcium from the cell in exchange for so-
dium. Magnesium is imported by the luminal transient recep-
tor potential cation channel subfamilyMmember 6 (TRPM6).
The basolateral exit pathways are thought to include a
basolateral Na/Mg exchanger [2–4, 16–18].
The clinical equivalent: the BDCT^ phenotype
Just as with loop dysfunction, impaired salt reabsorption in the
DCT causes characteristic electrolyte abnormalities. The im-
paired salt reabsorption and consequent volume loss leads to
increased renin and aldosterone levels, resulting in the
hypokalaemic, hypochloraemic metabolic alkalosis, common
to Bartter, Gitelman, and EAST syndromes. Yet, in contrast to
loop dysfunction, TGF is intact. Similarly, paracellular calci-
um reabsorption in the TAL is unaffected and patients typical-
ly have hypocalciuria, presumably due to a compensatory in-
crease in salt, and thus calcium reabsorption in the proximal
tubule [19].
Fig. 2. Electrolyte transport in the DCT. The NCC transporter imports
one sodium and one chloride ion from the lumen into the cell. This
transporter can be blocked by thiazide diuretics. Mutations in the gene
encoding NCC cause Gitelman syndrome. Chloride leaves the cell via the
basolateral CLCNKB channel, which needs the Barttin subunit in order to
function. Both proteins are expressed in both the TAL and DCT, and their
decreased function can cause Bartter syndrome (type 3 and type 4a,
respectively). Sodium can exit the cell via the basolateral Na-K-ATPase
that actively exports three sodium ions while importing two potassium
ions. Potassium is immediately recycled and pumped out of the cell by the
basolateral potassium channel KCNJ10, mutations in which cause EAST




Bartter syndrome (BS) was first described in 1962 by Frederic
Bartter [20]. Patients present with polyuria (which, depending
on the subtype, can manifest antenatally with polyhydramnios
and preterm birth), hypokalaemic, hypochloraemic metabolic
alkalosis and normal blood pressure in the context of elevated
renin and aldosterone levels. On a genetic basis, 5 different
subtypes are currently distinguished (Table 1) [3, 4, 21].
Bartter syndrome type 1 (BS1) is caused by mutations in
the gene encoding the luminal NKCC2 transporter, causing
polyhydramnios and premature birth. Patients have hypercal-
ciuria and nephrocalcinosis.
Bartter syndrome type 2 (BS2) is caused by mutations
disrupting the function of the luminal KCNJ1 channel, again
resulting in polyhydramnios and prematurity. Patients with
BS2 also show hypercalciuria and nephrocalcinosis. In addi-
tion, children with this type of BS typically have transient
hyperkalaemia in the neonatal period, as KCNJ1 also consti-
tutes a major pathway for potassium secretion in the collecting
duct. After the immediate neonatal period, other potassium
channels, most notably the so-called BK channels can com-
pensate for the loss of KCNJ1 in the CD; yet, patients with
BS2 typically have the highest plasma potassium levels of all
BS subforms [21, 22]. Because of the common presentation
with polyhydramnios and prematurity, BS1 and BS2 are often
classified as Bantenatal BS^ [13].
Bartter syndrome type 3 (BS3) is sometimes also referred
to as Bclassical BS,^ as patients with this subform typically
present postnatally and are thus closer to the original descrip-
tion by Bartter. BS3 is caused by a defective function of the
basolateral chloride channel CLCNKB, which is expressed
both in the TAL and the DCT. Affected children are usually
born at term and present in childhood with the typical electro-
lyte abnormalities. However, more severe phenotypes includ-
ing antenatal presentation with polyhydramnios have been
reported in a subset of patients. They can show hypercalciuria
and nephrocalcinosis, as well as hypomagnesemia.
Bartter syndrome type 4a (BS4a) is caused by disrupting
mutations in the gene encoding Barttin, a subunit of the
basolateral chloride channels CLCNKA and CLCNKB.
Type 4b (BS4b) is caused by simultaneous mutations in genes
encoding both CLCNKA and CLCNKB, giving a phenotype
similar to BS4a. Children with BS4 (a or b) typically present
with polyhydramnios and premature birth and can therefore
also be classified as Bantenatal BS.^ Patients can have hyper-
calciuria and nephrocalcinosis. Moreover, hypomagnesemia
can be found. Both these subtypes of BS are accompanied
by sensorineural deafness, since both chloride channels and
their Barttin subunit are expressed in the inner ear where the
efflux of chloride through these channels is needed to enable
depolarization of hair cells. Deafness only occurs if function
of both types of chloride channels is impaired, thus severely
hampering chloride transport. This is the case in BS4 but not
in BS3 where chloride transport via CLCNKA is still intact
[23].
All the previous described subtypes of BS are inherited in
an autosomal recessive manner. Recently, a transient but se-
vere antenatal form of X-linked BS was described, caused by
mutations in the gene encoding the protein melanoma-
associated antigen D2 (MAGE-D2). Patients present antena-
tally with severe polyhydramnios causing premature birth.
Table 1 Bartter, Gitelman, and EAST syndrome classification according to gene defect and clinical manifestation





601678 AR SLC12A1 NKCC2 Antenatal Nephrocalcinosis
Bartter syndrome
type 2




607364 AR CLCNKB ClC-Kb Variable Variable
Bartter syndrome
type 4a












300971 XLR MAGED2 MAGE-D2 Antenatal Transient Bartter syndrome,
nephrocalcionsis
Gitelman syndrome 263800 AR SLC12A3 NCCT Childhood Hypomagnesemia, hypocalciuria
EAST syndrome 612780 AR KCNJ10 Kir4.1 Infancy Epilepsy, ataxia, sensorineural deafness
# Besides hypokalaemic, hypochloraemic metabolic alkalosis
*Simultaneous mutations. AR, autosomal recessive; AD, autosomal dominant; XLR, X-linked recessive; NKCC2, Na-K-2Cl cotransporter; CLCNKA,
kidney chloride channel a; CLCNKB, kidney chloride channel b; MAGE-D2, melanoma-associated antigen D2; NCC, Na-Cl cotransporter; Na-K-2Cl
cotransporter, Na-K-2Cl cotransporter
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Again, there can be hypercalciuria, hypermagnesuria and
nephrocalcinosis. This entity is now considered the fifth sub-
type of Bartter syndrome (BS5) [24].
Finally, autosomal dominant or familial hypocalcaemia
can be associated with hypokalaemic, hypochloraemic met-
abolic alkalosis. Before the discovery of MAGED2 muta-
tions, this condition was sometimes referred to as Bartter
syndrome type 5, but is nowadays considered to be a
Bartter-like subform of familial hypocalcaemia. It is caused
by an activating mutation in the gene encoding the
basolateral calcium-sensing receptor (CaSR). Once activat-
ed, CaSR reduces the activity of KCNJ1, NKCC2, and the
Na-K-ATPase, thereby causing a phenotype that can mimic
BS. For this reason, this disorder has sometimes been called
BS type 5, but in the database Online Mendelian Inheritance
in Man (OMIM; www.omim.org), this classification is now
reserved to patients with mutations in MAGED2, as
discussed above. This is presumably to avoid assignation
o f two d i f f e r e n t n ame s ( a u t o s oma l dom in an t
hypocalcaemia and BS5) to the same disease.
Patients with autosomal dominant hypocalcaemia can pres-
ent at any age, but usually become symptomatic during ado-
lescence or in adulthood. In contrast to patients with BS, who
in general are normocalcaemic, patients with autosomal dom-
inant hypocalcaemia usually present with symptomatic
hypocalcaemia and hypercalciuria causing nephrocalcinosis.
Moreover, it has been shown that CaSR activation decreases
the activity of the basolateral inwardly rectifying potassium
channel KCNJ10, which ensures the recycling of potassium
over the basolateral membrane in order to maintain Na-K-
ATPase activity. The effect of CaSR activation on the DCT
can explain the hypomagnesemia that is often seen in patients
with familial hypocalcaemia [25, 26].
Gitelman syndrome
Gitelman syndrome (GS) was first described in 1966 by Hillel
Gitelman [27] (Table 1). It was initially thought to be a sub-
type of BS, given the similar clinical picture with
hypokalaemic, hypochloraemic metabolic alkalosis, but was
established as a separate entity by molecular genetics. It is
caused by mutations in the gene SLC12A3, encoding NCC
and is inherited in an autosomal recessive manner. As this
transporter is only expressed in DCT, GS is exclusively a
disorder of DCT. Patients typically present in late childhood
or adulthood with hypokalaemic, hypochloraemic metabolic
a l k a l o s i s a nd no rma l b l o od p r e s s u r e d e s p i t e
hyperaldosteronism, which can also be found in BS. Key fea-
tures at presentation in GS, however, are hypocalciuria (as
opposed to the hypercalciuria in BS) with hypermagnesuria.
In contrast to BS, overt hypomagnesaemia is typical for pa-
tients with GS. Chronic hypomagnesaemia is thought to cause
the development of chondrocalcinosis that can be a
complication in adult patients with GS. There can be some
degree of polyuria and polydipsia, but this is generally less
profound compared to patients with BS and, at least in child-
hood, urinary concentrating ability appears intact [21, 28].
Children with BS and GS have a reduced reabsorption of
sodium in the TAL and DCT, respectively. This results in an
increased tubular flow rate and an increased delivery of sodi-
um to the more distal nephron. In combination with activation
of the renin-angiotensin-aldosterone system (RAAS) caused
by chronic volume depletion and/or TGF dysfunction, this
will stimulate the reabsorption of sodium in the aldosterone-
sensitive part of the nephron with a concurrent increase in the
excretion of potassium and hydrogen ions, thus causing
hypokalaemic alkalosis [2]. Despite this pathological
hyperaldosteronism, patients with BS and GS are generally
normo- or even hypotensive. This can be explained by the
underlying tubulopathy, causing renal salt wasting.
Moreover, patients with BS and GS are found to have in-
creased levels of angiotensin-converting enzyme 2 (ACE2),
which results to increased conversion of angiotensinogen into
the vasodilatory peptide angiotensin 1–7. This opposes the
effect of ACE, which converts angiotensinogen into the vaso-
constrictive peptide angiotensin II [29]. Nevertheless, al-
though hypertension in childhood is rare, some adult patients
with GS develop hypertension. In one report, around 40% of
adult patients with GS suffer from high blood pressure [30].
Also, mutations can be found in genes causing BS and GS in
patients presenting with unexplained hypokalaemia and hy-
pertension [31]. The exact etiology of the high blood pressure
in this subset of patients remains to be elucidated, but is
t h o u g h t t o b e c a u s e d b y c h r o n i c s e c o n d a r y
hyperaldosteronism [30, 31].
Since the recycling of potassium across the luminal mem-
brane creates the driving force for paracellular absorption of
cations including calcium in the TAL, hypercalciuria causing
nephrocalcinosis is typical for the Bloop phenotype.^
Nephrocalcinosis is also seen in autosomal dominant
hypocalcaemia with Bartter-like syndrome, since hypercalci-
uria is a key symptom in this condition [3, 4]. In contrast, GS
is characterized by the combination of hypermagnesuria with
hypocalciuria. Hypermagnesuria is caused by decreased ex-
pression of the luminal magnesium channel TRPM6 in cells
lining the DCT. The exact pathway leading to the downregu-
lation of this transporter, however, remains unknown but is
probably related to DCTcell dysfunction due to the mutations
in NCC. The hypocalciuria that is typically seen in patients
with GS is caused by increased passive reabsorption of calci-
um in the PT. This is an effect that is secondary to the extra-
cellular volume contraction caused by increased sodium
wasting. Volume depletion triggers an increase of sodium re-
absorption in the PT, which in turn increases the electrochem-
ical gradient that drives the passive calcium transport in this
nephron segment [18, 19].
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Problems with the current classification
The initial classification of the different subtypes of BS main-
ly focused on the age at presentation, distinguishing antenatal
variants of BS (including BS1, BS2, BS4, and BS5, all typi-
cally associated with severe polyhydramnios causing prema-
ture birth) from classical BS (BS3). This classification mainly
serves the point of view of neonatologists who are faced with
patients in their first weeks of life, having the complications of
prematurity alongside the risk for severe fluid and electrolyte
problems if not monitored and supplemented aggressively.
However, some patients with BS3 can also present in the
antenatal period with moderate polyhydramnios and prema-
ture birth [22]. Because their presentation is earlier than usu-
ally seen in classical BS, these patients are sometimes marked
to have antenatal BS although their clinical phenotype is typ-
ically less severe compared to Btrue^ antenatal BS, thus caus-
ing confusion when this classification is used.
Another way to classify BS and GS, which is focused on
the underlying physiology, may be more appealing to the
(paediatric) nephrologist’s point of view. When using this
classification, BS is generally considered a disorder of TAL,
whereas GS is a disorder of DCT function. Yet, confusingly,
some subtypes of BS also affect the DCTand, in fact, BS3 can
be clinically indistinguishable from GS [3, 4, 21, 28, 32, 33].
For this reason, a classification has been proposed, separating
the various types into disorders of the TAL, the DCT, or of
both segments [13]. Disorders of the TAL are characterized by
hypercalciuria and nephrocalcinosis and are typically associ-
ated with an antenatal onset. Pharmacologically, they are
equivalent to the use of loop diuretics. The genetic causes
are usually mutations in SLC12A1 (NKCC2) or KCNJ1
(KCNJ1). In contrast, disorders of the DCT are characterized
by hypo- or normocalciuria, hypomagnesaemia and typically
manifest later in childhood or adolescence [3, 4, 21, 28]. The
pharmacologic equivalent here is thiazide diuretics and the
genetic causes are usually mutations in CLCNKB or
SLC12A3 (NCC). The Bcompound disorders^ affecting both
segments are usually caused by BSND (Barttin) or combined
CLCNKB/A mutations and typically have a severe clinical
phenotype with antenatal onset. Calcium excretion can be
variable.
This physiology-based classification makes perfect sense
when assessing patients at a given moment in time: if the
phenotype mimics a loop or thiazide diuretic or the combina-
tion of the two, the patient can be classified as having a TAL,
DCT, or combined disorder. But problems arise, when follow-
ing patients over time. And again, the confusing phenotypes
are those associated with mutations in CLCNKB. In fact, it is
interesting that the authors of this physiology-based classifi-
cation did not assign CLCNKB-based phenotypes to the
Bcompound disorders,^ although this channel, as discussed
above, is expressed in both segments, TAL and DCT. Yet,
clinically this makes sense, as most patients with BS type 4
(a and b) can easily be distinguished from BS3, based on their
earlier antenatal presentation, more severe polyhydramnios
and more complicated postnatal course (as well as the deaf-
ness) [34, 35]. Interestingly, BS3 can present either with a
Bloop^ or a BDCT^ phenotype, but not as a combined disorder
[32]. In fact, some patients appear to Bswitch^ phenotype,
initially presenting with a Bloop^ or BS phenotype and, during
later childhood and adolescence, develop the typical DCT or
GS phenotype [36]. If one were to apply the physiology-based
classification, then these patients would change diagnosis
from BS to GS over time, creating enormous potential for
confusion. There are also some clinical findings that argue
against equivocating BS3 with GS: the age of onset is usually
younger and complications, such as heavy proteinuria with
focal segmental glomerulosclerosis on histology, which pre-
sumably reflects persistent hyperreninism, but also growth
failure are virtually exclusively reported in BS3 [21, 32,
37–39]. For this reason, we propose to stick to a gene-based
classification, especially in countries where genetic analysis is
easily available.
Yet, apart from these problems with classification, the phe-
notypic Bswitch^ raises fascinating questions over the under-
lying pathophysiology: is there another basolateral chloride
exit pathway in the DCT that can provide some compensation
for loss of CLCNKB function, so that initially the Bloop^
phenotype predominates? If so, why is this compensatory
pathway apparently lost over time, so that the BDCT^ pheno-
type subsequently emerges? Or, considering that GS typically
presents in later childhood and adolescence, i.e., the time
frame of the phenotypic Bswitch,^ perhaps the initial Bloop^
phenotype just dominates the clinical picture in the first years
of life? Yet, how come the Bloop^ phenotype disappears? Is
the expression of CLCNKA increased over time, enabling it to
compensate for the loss of CLCNKB in the TAL?
Unfortunately, these questions are difficult to address, as
such a phenotypic Bswitch^ has not been described in the Clc-
k2 (the murine orthologue of CLCNKB) knock-out mice or
any other animal model [5, 40]. Yet, clinical observations in
other salt-wasting disorders have shown a similar develop-
ment with time of the DCT phenotype, e.g., in EAST/
SeSAME syndrome and the HNF1B-related tubulopathy
[41, 42]. Further observations, coupled with investigations in
the occasionally available biopsy tissue, or of Bliquid^ biop-
sies, e.g., urinary exosomes, may provide further insights over
time.
New insights
Bartter syndrome type 5
BS5 is the most recently discovered form of BS, and it raises
some fascinating questions regarding the developmental
Pediatr Nephrol
regulation of salt reabsorption [24]. BS5 is inherited in an X-
linked recessive manner. Male (and occasionally female) pa-
tients present antenatally with severe polyhydramnios, caus-
ing premature birth, sometimes before viability. But, most
fascinatingly, this newly described type of BS is transient
and symptoms resolve after the first weeks of life.
Genetic studies showed that this new BS subtype is caused
by mutations in the gene encoding the protein MAGE-D2.
Subsequent expression analysis revealed that MAGE-D2 is
expressed in the TAL and more distal nephron segments in
both developing and adult kidneys. It was shown that MAGE-
D2 increases the expression of NKCC2 in the TAL and NCC
in the DCT; in the absence of MAGE-D2, both transporters
were trapped in the endoplasmic reticulum, resulting in de-
creased expression at the luminal cell membrane. The reason
why this results in a transient phenotype remains to be eluci-
dated. It was hypothesized that other proteins could influence
NKCC2 and NCC expression during different stages of ges-
tation. Also, MAGE-D2 function could be altered by the re-
duced tissue oxygenation due to reduced kidney perfusion that
occurs physiologically after birth [24].Meanwhile, more cases
of this subtype of BS have been reported. In a large French
cohort, 17 out of 42 unsolved cases of antenatal BS were
found to be caused by mutations in the gene encoding
MAGE-D2. In all babies that survived the neonatal period,
BS was found to be transient. Interestingly, 2 of the reported
patients were female: the severe phenotype could be explained
by extremely skewed X-inactivation in 1 of them [43].
Urinary acidification and alkalinisation
Recently, new insights were gained in the urinary acidifying
properties of the TAL. It was generally believed that urinary
acidification after administration of loop diuretics, which
block NKCC2 and therefore mimic BS, was caused by the
increased load of sodium reaching the CD. In this nephron
segment, sodium is reabsorbed by the principal cells via the
specific sodium channel ENaC. The reabsorption of positively
charged sodium results in a voltage gradient, which facilitates
proton secretion by the type a intercalated cells via V-type H-
ATPase. Continuous increased urinary acid secretion will fi-
nally cause metabolic alkalosis, as is seen in BS. Yet, there are
two other potential pathways that could contribute:
Recent animal studies showed, however, that there is an-
other urinary acidification system that is activated after the
administration of furosemide. In the TAL, Nkcc2 co-
localizes with the Na/H exchanger type 3 (Nhe3). After the
administration of furosemide, luminal sodium reabsorption
through Nkcc2 stops but sodium continues to exit the cell
via the basolateral Na-K-ATPase. This will result in intracel-
lular sodium depletion, which is the driving force for Nhe3.
The latter reabsorbs sodium from the luminal fluid in
exchange for protons, thus causing urinary acidification and
intracellular alkalosis [44].
Moreover, it has been shown that the chloride transporter
CLCNKB is also expressed on the basolateral side of type a
(acid secreting) and type b (alkaline secreting) intercalated
cells in the collecting duct. Although acid secretion by type
a intercalated cells might be impaired in BS3, BS4a, and
BS4b, this is counteracted by a loss of bicarbonate secretion
by type b intercalated cells. The presence of an alkaline pH
activates CLCNKB (thereby increasing bicarbonate secretion
by type b intercalated cells), whereas the opposite is true in the
presence of an acidic pH. Due to this specific pH response,
impaired CLCNKB function in the collecting duct will mainly
affect type b intercalated cells. This could explain the pro-
found metabolic alkalosis that is typically seen in BS3 and
BS4, which is more severe compared to other subtypes of
BS [45, 46].
Paracellular sodium absorption in the TAL
In the healthy TAL, it is estimated that 50% of sodium is
reabsorbed via the previously described transcellular route
[47]. The other half is reabsorbed paracellularly via claudins
in the tight junctions, which depend on the lumen-positive
transepithelial potential. The tight junctions in the TAL either
consist of claudin 10b or a complex of claudin 3, claudin 16,
and claudin 19. Claudin 10b preferentially transports sodium
over calcium or magnesium, whereas the complex of claudins
3, 16, and 19 preferentially transports divalent cations like
calcium and magnesium [48].
Vasopressin can increase sodium reabsorption via the trans-
cellular route by increasing NKCC2 expression and activity
[49]. Increased sodium reabsorption in the TAL increases the
tonicity of the interstitial space, which in turn favors the reab-
sorption of water in the CD. More recently, it was discovered
that vasopressin can also increase sodium uptake via the
paracellular route, possibly via claudin 10b [50]. Whether
these recent findings on paracellular sodium transport could
be beneficial in the search for possible treatment options for
BS remains to be elucidated.
Future considerations
Although most patients with BS and GS nowadays have a
genetic confirmation of their diagnosis, there is still a signifi-
cant group of patients with a BS phenotype in whom no
disease-causing mutation could be detected. New techniques,
including whole-exome/genome sequencing, could identify
other genes that can cause BS and GS and increase our knowl-
edge of the exact mechanisms of tubular solute handling [3, 4,
21]. For instance, the recent discovery that vesicle-associated
membrane protein 3 (VAMP3) is needed for accurate intracel-
lular trafficking of NKCC2 to the luminal membrane, and that
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Vamp3-/- mice exhibit a BS phenotype, would make this an
interesting candidate gene [51]. Also, mutations in genes in-
volved in the phosphorylation of NKCC2 could decrease its
activity. Adenylyl cyclase 6 (AC6) is a crucial step in the
vasopressin-mediated phosphorylation of NKCC2. It has been
shown in a mouse model that deficiency of Ac6 results in low
Nkcc2 expression and a mild BS phenotype [49], which again
would make this an interesting candidate gene in unsolved
cases of BS. But it may not necessarily be new disease genes:
for instance, we described a patient with a clinical diagnosis of
GS, who subsequently was found to have a mutation in
HNF1B [33].
Our knowledge of tubular transporters and factors influenc-
ing their expression is rapidly increasing, but an effect of this
knowledge on the treatment of patients with tubulopathies still
lags behind. The treatment of BS and GS is still purely symp-
tomatic. In BS, the mainstay of treatment consists of adequate
fluid intake, replacement of sodium and potassium, and min-
imizing urinary losses water and electrolytes by the adminis-
tration of nonsteroidal anti-inflammatory drugs. Patients with
GS are often treated with a high-salt diet, combined with po-
tassium and magnesium supplements [3, 4, 21, 28]. Recently,
an animal study was published in which gene therapy was
used to successfully target the Nkcc2 gene with an adenoviral
vector to the TAL in vivo. To prevent adenoviral uptake by the
liver, the vector was directly injected into the renal artery.
Specific promotors were designed to target the vectors to their
assigned nephron segment. After transfection, exogenous and
endogenousNkcc2 were indeed co-expressed in the TAL [52].
This could be a first step towards gene therapy as a possible
curative treatment for tubulopathies like BS and GS, although
much more research is needed to ensure the long-term safety
of the viral vectors used and to ensure the permanent transfec-
tion of the target gene in a specific cell type with the end result
of a functioning transporter. Also, some recurrent mutations in
the gene encoding KCNJ1 alter protein folding, which in turn
results in these proteins being trapped in the endoplasmatic
reticulum and targeted for destruction by the endoplasmatic
reticulum-associated degradation pathway. These folding de-
fects could be corrected at low temperature in yeast cells [53].
That is a promising finding, since in other diseases like cystic
fibrosis folding defects that are correctable at low temperature
in yeast cells can now be corrected in man using chaperone
proteins [54]. Therefore, the possibilities to correct these
KCNJ1 folding defects and restore protein function should
be further studied and may provide a new therapy for a spe-
cific group of BS patients.
Conclusion
Our knowledge regarding the transporters that are expressed
in the TAL and the DCT is rapidly increasing, so is our
knowledge about the exact mechanisms that cause a BS or
GS phenotype. However, there is still much to learn about
proteins that are involved in the expression and activity of
these transporters. Since there is still a subgroup of patients
in whom no mutation can be found in the genes that are cur-
rently known to cause BS, the investigation of genes involved
in gene expression, protein trafficking, or transporter activity
could result in the discovery of new subtypes of the disease.
Moreover, the current treatment of BS and GS is only symp-
tomatic. Future studies should focus on possible curative treat-
ments for these diseases. The recent discoveries on how vaso-
pressin can increase paracellular sodium transport in the TAL
as well as studies performed using gene therapy to successful-
ly express NKCC2 in a murine model could be of importance
to find possible treatments for these conditions.
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